SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
1 report, 1 independent
Updated Sep 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
SynAct Pharma AB is seeking discussion with the FDA regarding the design of its Phase 3 clinical trials.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- TELIX Pharmaceuticals is conducting Phase 3 trials and seeking alignment on the New Drug Application pathway with the FDA.
- FDA placed a clinical hold on Phase 2/3 trials for SK Biopharm on September 1, 2026.
- The FDA granted Safe to Proceed for the Pivotal Phase 3 study of Vivace Therapeutics, Inc.
- Emmaus Life Sciences is conducting Phase 3 trials for an Endari drug, preceding future FDA submission.
- NewcelX Ltd. advanced its IND-enabling work for a Phase 1/2a trial and held a successful Type B Pre-IND meeting with the FDA.